In vitro findings support continued investigation of Bioxytran’s galectin-targeting approach against viruses related to avian influenza
BOSTON, MASSACHUSETTS — March 19, 2025 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics for viral diseases and other conditions involving tissue injury and hypoxia, today announced that it has entered into a Non-Disclosure Agreement (NDA) with the Board of Regents of the University System of Georgia, on behalf of the University of Georgia.
The agreement establishes a framework for research evaluating Bioxytran’s galectin antagonist technology as a potential approach for addressing avian influenza, commonly known as bird flu, in chickens.
The research will be led by Dr. Daniel Perez, a virology and poultry medicine expert at the University of Georgia. Dr. Perez holds several academic and research positions at the university, including CVI Affiliated Faculty and the Caswell Eidson Chair in Poultry Medicine.
Bioxytran’s lead antiviral candidate, ProLectin-M, is designed around a galectin-antagonist mechanism. Rather than directly targeting viral replication, the approach is intended to interfere with galectin-related processes that may play a role in viral infection and associated inflammatory responses.
Bioxytran has previously reported in vitro activity against viruses similar to avian influenza, providing the scientific basis for further investigation of the technology in the poultry setting.
The collaboration with the University of Georgia will allow researchers to evaluate whether this mechanism may have potential application against bird flu in chickens.
While the research is exploratory, the collaboration represents an opportunity to investigate Bioxytran’s galectin science beyond its initial human antiviral development program.
The University of Georgia collaboration also reflects Bioxytran’s broader strategy of applying its carbohydrate-based drug design capabilities to viral diseases.
Galectins are carbohydrate-binding proteins involved in a range of biological processes, and Bioxytran is investigating their potential role in viral infection and disease progression. ProLectin-M represents the company’s leading application of this research platform in antiviral drug development.
Research into avian influenza could provide additional insight into the broader applicability of galectin antagonism across viral systems.
Importantly, the University of Georgia research is investigational. The company has not established the safety or efficacy of ProLectin-M for treating avian influenza in chickens, and the program remains subject to further research and evaluation.
Bioxytran continues to advance its antiviral platform while exploring opportunities to apply its underlying science to additional viral threats.
The company’s research strategy is centered on glycovirology and carbohydrate-based drug design, with the goal of developing therapeutic candidates that act through mechanisms distinct from conventional antiviral approaches.
The University of Georgia collaboration provides another avenue for evaluating this technology and expanding the scientific understanding of galectin antagonists in viral disease.
Bioxytran, Inc. is a clinical-stage biotechnology company developing complex carbohydrate-based therapeutics for significant unmet medical needs. The company’s technology platforms include glycovirology, carbohydrate drug design, galectin science, and oxygen therapeutics.
Bioxytran’s lead antiviral candidate, ProLectin-M, is being investigated as a galectin antagonist for viral diseases. The company is also advancing research programs involving oxygen transport, pulmonary fibrosis, stroke, and other conditions associated with tissue injury and hypoxia.
This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements may include statements concerning Bioxytran’s research programs, collaborations, development plans, potential applications of its technologies, and the potential therapeutic value of its product candidates.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, among others, the outcome of research and development activities, the ability to advance product candidates through clinical and regulatory development, funding requirements, regulatory decisions, and other factors described in Bioxytran’s filings with the U.S. Securities and Exchange Commission.
Bioxytran undertakes no obligation to update any forward-looking statement except as required by applicable law.
For more information, visit Bioxytran, Inc..
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
